Skip to main content
SpringerLink
Log in

Brains, Bones, and Aging: Psychotropic Medications and Bone Health Among Older Adults

  • Epidemiology and Pathophysiology (RA Adler, Section Editor)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Psychotropic drugs are a crucial element of treatment for psychiatric disorders; however there is an established association between many classes of psychotropic medications and fracture risk among older adults, and growing evidence that some classes of medications may also impact bone mineral density (BMD). In this paper we review recent epidemiologic research on the association between psychotropic medications and osteoporosis, and discuss current controversies and unresolved issues surrounding this relationship. Key areas in need of focused inquiry include resolving whether the apparent association between psychotropic medications and BMD is due to confounding by indication, whether this relationship differs for men and women, and whether the implications of these medications for bone health vary over the life course. Clinical research to delineate the risk/benefit ratio of psychotropic medications for older adults, particularly those who are at high risk for fracture, is also needed to facilitate prescribing decisions between patients and physicians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. National Osteoporosis Foundation. [Online]. Available at: http://www.nof.org/node/40. Accessed August 14, 2012.

  2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–75.

    Article  PubMed  Google Scholar 

  3. US Department of Health and Human Services. Mental Health: a report of the Surgeon General. 1999.

  4. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66:848–56.

    Article  PubMed  Google Scholar 

  5. Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Aff (Millwood). 2005;24:195–205.

    Article  Google Scholar 

  6. Paulose-Ram R, Safran MA, Jonas BS, et al. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf. 2007;16:560–70.

    Article  PubMed  Google Scholar 

  7. National Institute for Health Care Management Research and Educational Foundation. Prescription Drug Expenditures in 2001: another year of escalating costs [Online]. Available at: http://www.nihcm.org/pdf/spending2001.pdf. Accessed August 14, 2012.

  8. Middleton N, Gunnell D, Whitley E, et al. Secular trends in antidepressant prescribing in the UK, 1975–1998. J Public Health Med. 2001;23:262–7.

    Article  PubMed  CAS  Google Scholar 

  9. Gartlehner G, Hansen RA, Morgan LC, et al. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review [internet]. Rockville: Agency for Healthcare Research and Quality; 2011.

    Google Scholar 

  10. •• Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51:606–13. Comprehensive review of the biological mechanisms linking SSRIs and bone mineral density.

    Article  PubMed  CAS  Google Scholar 

  11. •• Oderda LH, Young JR, Asche CV, et al. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother. 2012;46:917–28. Recent meta-analysis of the association between first-generation and second-generation antidepressant and antipsychotic drugs.

    Article  PubMed  Google Scholar 

  12. Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007;30:171–84.

    Article  PubMed  Google Scholar 

  13. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17:807–16.

    Article  PubMed  CAS  Google Scholar 

  14. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952–60.

    Article  PubMed  Google Scholar 

  15. Carbone LD, Johnson KC, Robbins J, et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women’s health initiative (WHI). J Bone Miner Res. 2010;25:873–81.

    PubMed  CAS  Google Scholar 

  16. Cetinkaya Y, Kurtulmus YS, Tutkavul K, et al. The effect of oxcarbazepine on bone metabolism. Acta Neurol Scand. 2009;120:170–5.

    Article  PubMed  CAS  Google Scholar 

  17. Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010;8:34–46.

    Article  PubMed  CAS  Google Scholar 

  18. Svalheim S, Roste LS, Nakken KO, et al. Bone health in adults with epilepsy. Acta Neurol Scand Suppl. 2011;(191):89–95.

  19. Triantafyllou N, Lambrinoudaki I, Armeni E, et al. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J Neurol Sci. 2010;290:131–4.

    Article  PubMed  CAS  Google Scholar 

  20. • Graham SM, Howgate D, Anderson W, et al. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf. 2011;10:575–602. Comprehensive review of the association between antipsychotics and bone mineralization and fracture incidence.

    Article  PubMed  CAS  Google Scholar 

  21. Renn JH, Yang NP, Chou P. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord. 2010;11:35.

    Article  PubMed  Google Scholar 

  22. • Bolton JM, Targownik LE, Leung S, et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31:56–60. Reports on the relationship between psychotropic medications, psychiatric disease, and osteoporosis in postmenopausal women.

    Article  PubMed  Google Scholar 

  23. Bolton JM, Metge C, Lix L, et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28:384–91.

    Article  PubMed  Google Scholar 

  24. Mezuk B, Morden NE, Ganoczy D, et al. Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration. Am J Geriatr Psychiatr. 2010;18:245–55.

    Article  Google Scholar 

  25. Mezuk B. Affective disorders, bone metabolism, and osteoporosis. 2008;6:101–102–13.

  26. Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008;23:567–74.

    Article  PubMed  Google Scholar 

  27. Mezuk B, Eaton WW, Golden SH, et al. Depression, antidepressants, and bone mineral density in a population-based cohort. J Gerontol A Biol Sci Med Sci. 2008;63:1410–5.

    Article  PubMed  Google Scholar 

  28. Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone. 2010;46:13–7.

    Article  PubMed  CAS  Google Scholar 

  29. Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008;28:411–7.

    Article  PubMed  CAS  Google Scholar 

  30. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003;158:77–84.

    Article  PubMed  Google Scholar 

  31. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188–94.

    Article  PubMed  CAS  Google Scholar 

  32. Hamed SA. Influences of bone and mineral metabolism in epilepsy. Expert Opin Drug Saf. 2011;10:265–80.

    Article  PubMed  CAS  Google Scholar 

  33. Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies. Osteoporos Int. 2012;23:365–75.

    Article  PubMed  CAS  Google Scholar 

  34. Ashjazadeh N, Zamani A, Pourjafar M, et al. Bone density of ambulatory adult patients receiving long-term anticonvulsant drug therapy. Arch Iran Med. 2009;12:550–4.

    PubMed  Google Scholar 

  35. Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69:385–91.

    Article  PubMed  CAS  Google Scholar 

  36. Kunimatsu T, Kimura J, Funabashi H, et al. The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regul Toxicol Pharmacol. 2010;58:360–8.

    Article  PubMed  CAS  Google Scholar 

  37. Pack AM. Genetic variation may clarify the relationship between epilepsy, antiepileptic drugs, and bone health. Eur J Neurol. 2011;18:3–4.

    Article  PubMed  CAS  Google Scholar 

  38. Bliziotes MM, Eshleman AJ, Zhang XW, et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29:477–86.

    Article  PubMed  CAS  Google Scholar 

  39. Calarge CA, Zimmerman B, Xie D, et al. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010;71:338–47.

    Article  PubMed  CAS  Google Scholar 

  40. Calarge CA, Ellingrod VL, Zimmerman B, et al. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011;72:1685–90.

    Article  PubMed  CAS  Google Scholar 

  41. Haney EM, Warden SJ. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact. 2008;8:133–45.

    PubMed  CAS  Google Scholar 

  42. Warden SJ, Robling AG, Sanders MS, et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology. 2005;146:685–93.

    Article  PubMed  CAS  Google Scholar 

  43. Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19:1420–31.

    Article  PubMed  CAS  Google Scholar 

  44. Bliziotes M, Eshleman A, Burt-Pichat B, et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone. 2006;39:1313–21.

    Article  PubMed  CAS  Google Scholar 

  45. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int. 2011;88:476–84.

    Article  PubMed  CAS  Google Scholar 

  46. Chau K, Atkinson SA, Taylor VH. Are selective serotonin reuptake inhibitors a secondary cause of low bone density? J Osteoporos. 2012;2012:323061.

    PubMed  Google Scholar 

  47. Pack AM, Reddy DS, Duncan S, et al. Neuroendocrinological aspects of epilepsy: important issues and trends in future research. Epilepsy Behav. 2011;22:94–102.

    Article  PubMed  Google Scholar 

  48. Pack AM, Walczak TS. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol. 2008;83:305–28.

    Article  PubMed  Google Scholar 

  49. Verrotti A, Coppola G, Parisi P, et al. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010;112:1–10.

    Article  PubMed  Google Scholar 

  50. Beerhorst K, Schouwenaars FM, Tan IY, et al. Epilepsy: fractures and the role of cumulative antiepileptic drug load. Acta Neurol Scand. 2012;125:54–9.

    Article  PubMed  CAS  Google Scholar 

  51. El-Hajj Fuleihan G, Dib L, Yamout B, et al. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone. 2008;43:149–55.

    Article  PubMed  CAS  Google Scholar 

  52. Lado F, Spiegel R, Masur JH, et al. Value of routine screening for bone demineralization in an urban population of patients with epilepsy. Epilepsy Res. 2008;78:155–60.

    Article  PubMed  Google Scholar 

  53. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med. 2004;71 Suppl 2:S42–8.

    Article  PubMed  Google Scholar 

  54. Heo K, Rhee Y, Lee HW, et al. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia. 2011;52:1884–9.

    Article  PubMed  CAS  Google Scholar 

  55. Erel T, Guralp O. Epilepsy and menopause. Arch Gynecol Obstet. 2011;284:749–55.

    Article  PubMed  Google Scholar 

  56. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28 Suppl 2:55–68.

    Article  PubMed  CAS  Google Scholar 

  57. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28 Suppl 2:109–23.

    Article  PubMed  CAS  Google Scholar 

  58. Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94:246–54.

    Article  PubMed  CAS  Google Scholar 

  59. Bataille-Simoneau N, Gerland K, Chappard D, et al. Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun. 1996;229:323–8.

    Article  PubMed  CAS  Google Scholar 

  60. Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem. 2009;107:677–85.

    Article  PubMed  CAS  Google Scholar 

  61. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol. 2004;57:1223–31.

    Article  PubMed  Google Scholar 

  62. Thomas D, Stram D, Dwyer J. Exposure measurement error: influence on exposure-disease. Relationships and methods of correction. Annu Rev Public Health. 1993;14:69–93.

    Article  PubMed  CAS  Google Scholar 

  63. Mojtabai R. Unmet need for treatment of major depression in the United States. Psychiatr Serv. 2009;60:297–305.

    Article  PubMed  Google Scholar 

  64. Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int. 2008;19:1–12.

    Article  PubMed  CAS  Google Scholar 

  65. Bab I, Yirmiya R. Depression, selective serotonin reuptake inhibitors, and osteoporosis. Curr Osteoporos Rep. 2010;8:185–91.

    Article  PubMed  Google Scholar 

  66. Cizza G, Primma S, Coyle M, et al. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res. 2010;42:467–82.

    Article  PubMed  CAS  Google Scholar 

  67. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.

    Article  Google Scholar 

  68. Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods. 2010;15:234–49.

    Article  PubMed  Google Scholar 

  69. Stuart EA, Marcus SM, Horvitz-Lennon MV, et al. Using non-experimental data to estimate treatment effects. Psychiatr Ann. 2009;39:41451.

    Article  PubMed  Google Scholar 

  70. Wu Q, Magnus JH, Liu J, et al. Depression and low bone mineral density: a meta-analysis of epidemiologic studies. Osteoporos Int. 2009;20:1309–20.

    Article  PubMed  CAS  Google Scholar 

  71. Rey-Sanchez P, Lavado-Garcia JM, Canal-Macias ML, et al. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol. 2009;24:49–54.

    Article  PubMed  Google Scholar 

  72. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229.

    Article  PubMed  Google Scholar 

  73. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167:1246–51.

    Article  PubMed  Google Scholar 

  74. • Cizza G, Mistry S, Nguyen VT, et al. Do premenopausal women with major depression have low bone mineral density? a 36-month prospective study. PLoS One. 2012;7:e40894. Investigation of the influence of major depression on osteoporosis risk among younger women.

    Article  PubMed  CAS  Google Scholar 

  75. Eskandari F, Martinez PE, Torvik S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329–36.

    Article  PubMed  Google Scholar 

  76. Battaglino R, Vokes M, Schulze-Spate U, et al. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem. 2007;100:1387–94.

    Article  PubMed  CAS  Google Scholar 

  77. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–78.

    Article  PubMed  CAS  Google Scholar 

  78. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief. 2010;(42):1–8.

  79. Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516–23.

    Article  PubMed  Google Scholar 

  80. Caughey GE, Roughead EE, Shakib S, et al. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age Ageing. 2010;39:488–94.

    Article  PubMed  Google Scholar 

  81. Gosch M, Jeske M, Kammerlander C, et al. Osteoporosis and polypharmacy. Z Gerontol Geriatr. 2012.

  82. Kojima T, Akishita M, Nakamura T, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12:425–30.

    Article  PubMed  Google Scholar 

  83. Kao S, Wang YC, Tzeng YM, et al. Interactive effect between depression and chronic medical conditions on fall risk in community-dwelling elders. Int Psychogeriatr. 2012;24:1409–18.

    Article  PubMed  Google Scholar 

  84. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989–95.

    Article  PubMed  Google Scholar 

  85. Kragh A, Elmstahl S, Atroshi I. Older adults’ medication use 6 months before and after hip fracture: a population-based cohort study. J Am Geriatr Soc. 2011;59:863–8.

    Article  PubMed  Google Scholar 

  86. Slomski A. Falls from taking multiple medications may be a risk for both young and old. JAMA. 2012;307:1127–8.

    Article  PubMed  CAS  Google Scholar 

  87. Petty DR, House A, Knapp P, et al. Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing. 2006;35:523–6.

    Article  PubMed  Google Scholar 

  88. Dickinson R, Knapp P, House AO, et al. Long-term prescribing of antidepressants in the older population: a qualitative study. Br J Gen Pract. 2010;60:e144–55.

    Article  PubMed  Google Scholar 

  89. Lasserre A, Younes N, Blanchon T, et al. Psychotropic drug use among older people in general practice: discrepancies between opinion and practice. Br J Gen Pract. 2010;60:e156–62.

    Article  PubMed  Google Scholar 

  90. Siriwardena AN. Why do GPs prescribe psychotropic drugs when they would rather provide alternative psychological interventions? Br J Gen Pract. 2010;60:241–2.

    Article  PubMed  Google Scholar 

  91. Middleton H, Moncrieff J. ‘They won’t do any harm and might do some good’: time to think again on the use of antidepressants? Br J Gen Pract. 2011;61:47–9.

    Article  PubMed  Google Scholar 

  92. •• Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551. Large study of adverse clinical events due to pharmacologic treatment of depression among older adults.

    Article  PubMed  Google Scholar 

  93. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300:2417–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

The authors reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Department of Epidemiology and Community Health, Virginia Commonwealth University School of Medicine, PO Box 980212, Richmond, VA, 23238, USA

    Monique J. Brown & Briana Mezuk

Authors
  1. Monique J. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Briana Mezuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Briana Mezuk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, M.J., Mezuk, B. Brains, Bones, and Aging: Psychotropic Medications and Bone Health Among Older Adults. Curr Osteoporos Rep 10, 303–311 (2012). https://doi.org/10.1007/s11914-012-0121-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-012-0121-4

Keywords

Search

Navigation